Last mentioned: Mar 7, 2026
Annual Progress Review
First assessment of the 15th Five-Year Plan's initial biotech milestones.
R&D Tax Incentive Launch
Specialized tax breaks for high-tech biotech firms are rolled out nationwide.
NMPA Reform Implementation
New guidelines for accelerated clinical trial approvals take effect.
15th FYP Announcement
China officially prioritizes tech self-reliance as the central pillar of the 2026-2030 plan.
Policy Framework Unveiled
China details the 2026 policy mix focusing on innovation and global sharing.
Implementation Phase
Expected rollout of specific subsidies and domestic-first procurement policies.
Geopolitical Escalation
U.S. introduces Biosecure Act, targeting major Chinese biotech entities.
14th Five-Year Plan
Initial focus on 'Dual Circulation' and building basic biotech infrastructure.
China has officially signaled a shift toward total technological self-reliance in its 15th Five-Year Plan, prioritizing the domestic life sciences and pharmaceutical sectors. This strategic pivot aims to insulate China’s healthcare infrastructure from global supply chain volatility and geopolitical pressures while fostering a homegrown innovation ecosystem.
China has detailed a comprehensive 2026 policy framework aimed at accelerating domestic biotech innovation while expanding international market access. The initiative prioritizes 'new quality productive forces' in drug development and streamlines regulatory pathways for global pharmaceutical collaborations.